In life sciences, the end goal of improving patient outcomes rarely changes. What has changed, quite dramatically, is the environment in which innovation must survive long enough to get there.
For early-stage companies in particular, the path from idea to impact is becoming harder to navigate. Capital is tighter, IPO windows have narrowed, and policy and macroeconomic conditions remain unpredictable. At the same time, global competition is intensifying, and the centres of innovation are shifting. Never has a robust intellectual property (“IP”) strategy been more critical.
A Market Under Pressure
Recent market activity illustrates this point. In the US, 2025 saw one of the weakest years for biotech IPOs in over a decade, with only nine companies listing. This is unlikely to be an isolated anomaly, but rather a reflection of a broader cooling in public market appetite for biotech, driven by weak sector performance, high interest rates, and a general shift away from risk.
This is only one side of the story. At the same time, the pharmaceutical sector is heading towards an unprecedented patent cliff, with more than $300 billion in drug revenues set to lose exclusivity between 2025 and 2030, as patents expire on nearly 200 products, including dozens of blockbusters. Companies therefore face rapid revenue erosion, often losing up to 80% of revenues within a year of generic or biosimilar entry. For large pharmaceutical companies, this creates immediate pressure to identify and secure new sources of value to mitigate against such a sharp drop.
The consequence is a market that feels constrained in one direction and highly active in another. While IPO activity has slowed, mergers and acquisitions and licensing activity remain strong. Transactions are happening, and at scale, but with a clear bias: large pharmaceutical companies are focusing on later-stage or near-commercial assets, where development risk is lower and the path to revenue is clearer.
A Divided Landscape
This has created a pronounced divide across the life sciences ecosystem. Later-stage biotech companies, particularly those with clinical or near-market assets, are in a relatively strong position. Demand remains strong, and competition between acquirers can drive attractive valuations.
Early-stage companies, by contrast, are operating in a much tougher funding environment. Traditional routes to capital are less reliable, and many are having to think earlier about partnerships, licensing strategies, or positioning for acquisition.
In this context, IP strategy becomes critical.
IP As the Core Asset
For an early-stage life sciences company, IP is what investors assess, what partners evaluate, and what acquirers ultimately buy.
A well-constructed patent portfolio can reduce perceived risk, create multiple pathways to monetisation, and support higher valuations. Conversely, a weak or poorly structured IP strategy can limit strategic options and undermine commercial outcomes.
Despite this, IP strategy is still too often treated as something that can be deferred to a later stage – in the current climate, that is a risk few companies can afford. Investing in an IP strategy early on (e.g. what to file, when to file, and how those filings evolve over time) can pay significant dividends for both commercial flexibility and exit opportunities.
Building an Effective IP Strategy
A company aiming for acquisition will structure its portfolio differently from one planning to commercialise independently. Likewise, a business expecting to rely heavily on licensing will need to think carefully about how clearly and broadly its core technology is protected, and how easily that protection can be understood and valued by third parties.
From there, execution becomes a matter of discipline and continuity. Early filings remain essential, particularly in fast-moving or competitive fields, but a single filing is rarely enough. Value is built over time through layered protection, follow-on patent applications that capture improvements, variations, and new uses, gradually strengthen the overall position and make it more difficult for competitors to design around.
There is also a more strategic dimension that is sometimes overlooked. If acquisition is a realistic outcome, it can be worth thinking in advance about who the likely acquirers might be. Understanding how your technology fits alongside their existing portfolios can inform your filing strategy in subtle but important ways. Patents that align with, extend, or reinforce an acquirer’s position can carry disproportionate weight in a transaction, leading to higher company valuations.
As companies mature, freedom to operate comes more to the fore. Demonstrating a clear understanding of the surrounding IP landscape, and the nature of competing rights, can significantly enhance credibility with investors and partners. In a more risk-averse funding environment, that kind of clarity is increasingly valuable.
A Shifting Global Landscape
Alongside these strategic considerations, the geographic dimension of IP is evolving. For many years, the default approach in life sciences was to focus heavily on the US and Europe. Those jurisdictions remain central, but the balance is shifting.
In the US, there are signs of strain within the patent system. Operational disruption at the United States Patent and Trademark Office combined with changes to examination processes is creating greater uncertainty around timelines to grant. For companies reliant on patent protection to support investment and partnering, this unpredictability can have tangible commercial consequences.
Europe, by contrast, has remained relatively stable. The European Patent Office continues to process a high proportion of cases in line with targets, and in many instances offers a more predictable route to grant. That reliability can be valuable when coordinating multi-jurisdictional strategies.
Perhaps the most significant change is the continued rise of Asia, particularly China. Patent filing activity in this region has grown rapidly, far outpacing historical trends in other regions. This is not just a numbers story – it reflects a broader shift in where innovation is happening and how it is being commercialised.
The Rise of Cross-Border Licensing
A result of this shift is the increasing importance of cross-border licensing. As supply chains become more uncertain, affected by tariffs, policy changes, and geopolitical tensions, companies increasingly look for ways to reduce reliance on the physical movement of goods. Licensing allows businesses to access and commercialise innovation across jurisdictions without relying on physical product movement.
This approach brings its own complexities, particularly in relation to manufacturing, tax and structuring considerations. However, it also offers increased flexibility and can enable more efficient global deployment of innovation while retaining greater control over supply chains and cost structures.
The growth of outbound licensing from China is a clear example of this trend. Deal volumes and values have increased significantly, particularly in high-value therapeutic areas such as oncology and advanced biologics. Notably, many of these transactions involve relatively early-stage assets that combine strong scientific differentiation with clear commercial potential.
Standing Out in a More Competitive Market
For UK-based life sciences companies, the implications are clear. Competition is becoming more global, more strategic, and more selective.
Strong science remains essential, but it is not sufficient on its own. Companies must be able to demonstrate a clear and coherent approach to intellectual property – one that supports their commercial strategy, aligns with market expectations, and resonates with investors and acquirers.
That means thinking early, acting deliberately, and building a portfolio that not only protects the core innovation but also tells a compelling commercial story.
In today’s market, patents are not just defensive tools, they are strategic assets that can unlock funding, enable partnerships, and ultimately determine whether an innovation reaches the patients it is intended to serve.
